Argenx CEO Shares Secrets Of Vyvgart’s Stellar Success

Commercial Strategy In Place Early

22 Aug 2022

Leaving commercial hires to just a few months before drug approval is a mistake, Argenx CEO Tim Van Hauwermeiren tells Scrip, noting that the impressive launch achieved for Vyvgart for generalized myasthenia gravis in the US and Japan will be a steadier affair in Europe.

Red-tailed Hawk flying over the mountains with sky background — Argenx is flying high • Source: Shutterstock

Any ambitious biotech that wishes to go it alone on the market needs to get its key commercial team in place before planning late-stage studies, according to Tim Van Hauwermeiren, CEO of argenx N.V..

Van Hauwermeiren's views come with considerable weight given the stellar launch Argenx has enjoyed with Vyvgart (efgartigimod) which was approved...